CN111408733A - Antibacterial and antiviral nano silver colloidal solution and preparation method and application thereof - Google Patents
Antibacterial and antiviral nano silver colloidal solution and preparation method and application thereof Download PDFInfo
- Publication number
- CN111408733A CN111408733A CN202010326618.2A CN202010326618A CN111408733A CN 111408733 A CN111408733 A CN 111408733A CN 202010326618 A CN202010326618 A CN 202010326618A CN 111408733 A CN111408733 A CN 111408733A
- Authority
- CN
- China
- Prior art keywords
- solution
- antibacterial
- antiviral
- nano
- silver colloidal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 title claims abstract description 120
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 83
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 52
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 52
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 34
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 27
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 27
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 27
- 229940033123 tannic acid Drugs 0.000 claims abstract description 27
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 27
- 229920002258 tannic acid Polymers 0.000 claims abstract description 27
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 26
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 26
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 26
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 26
- -1 salicylic acid compound Chemical class 0.000 claims abstract description 21
- 229910001961 silver nitrate Inorganic materials 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 17
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 16
- 229960004025 sodium salicylate Drugs 0.000 claims description 16
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 12
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 12
- LWUQBSVJOMGTOY-UHFFFAOYSA-N 2-acetyloxybenzoic acid;calcium;urea Chemical compound [Ca].NC(N)=O.CC(=O)OC1=CC=CC=C1C(O)=O LWUQBSVJOMGTOY-UHFFFAOYSA-N 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 6
- 239000004332 silver Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 description 190
- 241000700605 Viruses Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 18
- 241000712461 unidentified influenza virus Species 0.000 description 16
- 230000035931 haemagglutination Effects 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 241000233866 Fungi Species 0.000 description 10
- VYMUGTALCSPLDM-UHFFFAOYSA-L carbasalate calcium Chemical compound [Ca+2].NC(N)=O.CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O VYMUGTALCSPLDM-UHFFFAOYSA-L 0.000 description 10
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 8
- 241000711404 Avian avulavirus 1 Species 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 6
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000588626 Acinetobacter baumannii Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000027645 antigenic variation Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 description 1
- 229940019931 silver phosphate Drugs 0.000 description 1
- 229910000161 silver phosphate Inorganic materials 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- WYCFMBAHFPUBDS-UHFFFAOYSA-L silver sulfite Chemical compound [Ag+].[Ag+].[O-]S([O-])=O WYCFMBAHFPUBDS-UHFFFAOYSA-L 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/16—Making metallic powder or suspensions thereof using chemical processes
- B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
- B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/408—Virucides, spermicides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Pain & Pain Management (AREA)
- Composite Materials (AREA)
- Rheumatology (AREA)
- Birds (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
The embodiment of the invention relates to the technical field of medical health, and particularly discloses an antibacterial and antiviral nano-silver colloidal solution and a preparation method and application thereof. The preparation method of the antibacterial and antiviral nano silver colloidal solution comprises the following steps: slowly adding silver nitrate into the salicylic acid compound solution and fully stirring to prepare an intermediate solution; and sequentially and slowly adding a tannic acid solution, a sodium carbonate solution and a polyvinylpyrrolidone solution into the intermediate solution and fully stirring to prepare the antibacterial and antiviral nano-silver colloidal solution. The embodiment of the invention can solve the technical problem that the nano-silver colloidal solution in the prior art cannot well overcome the instability of the nano-silver, and simultaneously enhances the broad-spectrum antibacterial and antiviral effects of the nano-silver in the nano-silver colloidal solution.
Description
Technical Field
The invention relates to the technical field of medical treatment and health, in particular to an antibacterial and antiviral nano-silver colloidal solution and a preparation method and application thereof.
Background
Since Olympic Gentiansis (Ivanovski) discovered Nicotiana tabacum virus in 1898, more than 400 kinds of viruses associated with human diseases were discovered, and it was counted that more than 90% of human respiratory infectious diseases are caused by viruses, and many viral diseases such as smallpox, measles, poliomyelitis, etc. were effectively controlled with the development of immunology, however, many viruses which are not very antigenic and are liable to mutation, such as influenza Virus, SARS (Severe acute respiratory syndrome) coronavirus, avian influenza Virus, Human Immunodeficiency Virus (HIV), and new coronavirus, are difficult to control, are sometimes or currently circulating in a relatively serious situation, and are also diseases caused by bacteria, these pose serious threats to human health, and thus, prevention of bacterial and viral infections remains a major and urgent task for humans.
Among them, respiratory viruses such as influenza virus, SARS coronavirus, avian influenza virus, and novel coronavirus are difficult to control, and the main reason is that these viruses are infected on the mucosal surface, have weak antigenicity, and are prone to antigenic variation and drug-resistant mutation, resulting in poor viral drug resistance and viral vaccine immunization. Therefore, in the face of the characteristics of various human respiratory viruses, mucosal surface infection, weak antigenicity, easy antigenic variation and drug resistance mutation, the active search for a broad-spectrum nonspecific antibacterial and antiviral solution which is safe, effective and suitable for mucosal surface application is of great significance.
The nano silver is prepared by nano technology, the nano metal silver has strong bactericidal capacity, after the nano silver is prepared, the particle size reaches a nano (nm) level state, the nano silver has larger specific surface area, and the smaller the material unit of the nano silver is, the more the nano silver can effectively contact bacteria and viruses. In the prior art, nano silver is prepared into various antibacterial and antiviral products such as nano silver colloidal solution, is safe and effective, has no drug resistance, has multi-target 'attack' effect on various bacteria, fungi and viruses, has broad-spectrum antibacterial, antifungal and antiviral effects, and is suitable for application on the surface of a mucous membrane. However, in the prior art, the nano silver colloidal solution cannot well overcome the defect that nano silver is not stable enough, so that the wide application of nano silver in the field of medicines with broad-spectrum antibacterial and antiviral effects is limited.
Therefore, how to provide a safe, effective, non-drug-resistant, broad-spectrum antibacterial and antiviral nano-silver colloidal solution suitable for mucosal surface application and sufficiently stable is a technical problem to be solved.
Disclosure of Invention
The embodiment of the invention aims to provide an antibacterial and antiviral nano-silver colloidal solution, a preparation method thereof and application thereof in preparing antibacterial materials or antibacterial drugs, which can solve the technical problem that the nano-silver colloidal solution in the prior art cannot well overcome the instability of nano-silver, and can enhance the broad-spectrum antibacterial and antiviral effects of the nano-silver in the nano-silver colloidal solution.
On one hand, the embodiment of the invention provides a preparation method of an antibacterial and antiviral nano silver colloidal solution, which comprises the following steps: slowly adding silver nitrate into the salicylic acid compound solution and fully stirring to prepare an intermediate solution; and sequentially and slowly adding a tannic acid solution, a sodium carbonate solution and a polyvinylpyrrolidone solution into the intermediate solution and fully stirring to prepare the antibacterial and antiviral nano-silver colloidal solution.
In one embodiment of the present invention, the method for preparing the antibacterial and antiviral nano silver colloid solution further comprises the steps of: and storing the antibacterial and antiviral nano silver colloid solution in a brown bottle for later use.
In one embodiment of the present invention, the salicylic acid compound solution is selected from any one of an acetylsalicylic acid solution, a sodium salicylate solution, a salicylic acid solution, and a calcium acetylsalicylate urea solution.
In one embodiment of the invention, the content of the acetylsalicylic acid in the acetylsalicylic acid solution is 2 mg/ml, the content of the sodium salicylate in the sodium salicylate solution is 2-5 mg/ml, the content of the salicylic acid in the salicylic acid solution is 1-2 mg/ml, and the content of the calcium acetylsalicylic acid urea in the calcium acetylsalicylic acid urea solution is 2-5 mg/ml.
In one embodiment of the invention, the agitation is achieved using a magnetic stirrer.
In one embodiment of the present invention, the content of silver ions in the intermediate solution is 0.4 to 0.8 mg/ml, the content of tannic acid in the tannic acid solution is 5 to 10 mg/ml, the content of sodium carbonate in the sodium carbonate solution is 5 to 10 mg/ml, the content of polyvinylpyrrolidone in the polyvinylpyrrolidone solution is 10 to 20 mg/ml, and the volume ratio of the intermediate solution, the tannic acid solution, the sodium carbonate solution, and the polyvinylpyrrolidone solution is 88: 3: 2: 7.
In one embodiment of the present invention, the average particle size of the nano silver particles in the antibacterial and antiviral nano silver colloidal solution is 42.30 nm.
In one embodiment of the present invention, the zeta potential of the nano silver particles in the antibacterial and antiviral nano silver colloidal solution is-19.8 mv.
In another aspect, an antibacterial and antiviral nano-silver colloidal solution is provided, which is prepared by the method for preparing the antibacterial and antiviral nano-silver colloidal solution according to any one of the embodiments.
In still another aspect, an embodiment of the present invention provides a use of the antibacterial and antiviral nano-silver colloidal solution as described in any one of the preceding embodiments in preparing an antibacterial and antiviral material or an antibacterial and antiviral drug.
The previous embodiment of the present invention is to prepare an intermediate solution by slowly adding silver nitrate to a salicylic acid compound solution and sufficiently stirring; and the tannic acid solution, the sodium carbonate solution and the polyvinylpyrrolidone solution are sequentially and slowly added into the intermediate solution and fully stirred to prepare the safe, effective, drug-resistance-free, broad-spectrum antibacterial and antiviral nano-silver colloidal solution which is suitable for application on the surface of a mucous membrane and is stable enough.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without creative efforts.
Fig. 1 is a schematic flow chart of a method 100 for preparing an antibacterial and antiviral nano silver colloidal solution according to an embodiment of the present invention;
fig. 2 is a graph showing the particle size of nano silver particles in the antibacterial and antiviral nano silver colloidal solution prepared in example 1;
fig. 3 is a zeta potential diagram of nano silver particles in the antibacterial and antiviral nano silver colloidal solution prepared in example 1.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example one
As shown in fig. 1, an embodiment of the present invention provides a method 100 for preparing an antibacterial and antiviral nano silver colloidal solution, where the method 100 mainly includes:
step S110: silver nitrate was slowly added to the salicylic acid compound solution and stirred well to make an intermediate solution. The silver nitrate may be replaced by other suitable silver salts besides silver nitrate, such as silver sulfate, silver sulfite, silver phosphate, etc. And
step S130: and sequentially and slowly adding a tannic acid solution, a sodium carbonate solution and a polyvinylpyrrolidone solution into the intermediate solution, and fully stirring to prepare the antibacterial and antiviral nano-silver colloidal solution.
Further, the preparation method of the antibacterial and antiviral nano silver colloid solution further comprises the following steps: step S150: and storing the antibacterial and antiviral nano silver colloid solution in a brown bottle for later use. Of course, the antibacterial and antiviral nano silver colloid solution can also be stored in other opaque dark colored bottles for standby.
Wherein the salicylic acid compound solution is selected from any one of an acetylsalicylic acid solution, a sodium salicylate solution, a salicylic acid solution and a calcium acetylsalicylate urea solution. Of course, the salicylic acid compound solution includes, but is not limited to, the above-mentioned acetylsalicylic acid solution, sodium salicylate solution, salicylic acid solution and acetylsalicylic acid calcium urea solution, and other salicylic acid compound solutions such as salicylic acid drug solutions are also possible.
In addition, it should be noted that the concentrations and volume ratios of the raw materials involved in the preparation of the antibacterial and antiviral nano silver colloidal solution in the preparation method 100 of the antibacterial and antiviral nano silver colloidal solution according to the first embodiment of the present invention may be reasonably selected and configured by those skilled in the art according to the technical solutions disclosed in the first embodiment of the present invention, in combination with the practical situations, the protection scope of the present invention includes, but is not limited to, the values or value ranges of the concentrations and volume ratios listed in the first embodiment of the present invention, and the values or value ranges of the concentrations and volume ratios listed in the first embodiment of the present invention are only preferred examples.
It is also worth mentioning that the embodiment of the present invention may further include a step of preparing each raw material involved in the antibacterial and antiviral nano silver colloid solution, for example. In addition, in other embodiments, the raw materials involved in the preparation of the antibacterial and antiviral nano-silver colloidal solution may be replaced by the components before the preparation of the raw materials, and accordingly, the preparation method of the antibacterial and antiviral nano-silver colloidal solution may be suitably modified accordingly.
For example, the salicylic acid compound solution may be an acetylsalicylic acid solution with an acetylsalicylic acid content of 2 mg/ml.
In addition, the salicylic acid compound solution can be sodium salicylate solution with the content of sodium salicylate of 2-5 mg/ml. Specifically, the content of sodium salicylate in the sodium salicylate solution is 2 mg/ml, 2.5 mg/ml, 4 mg/ml, 5 mg/ml and the like, and preferably, the content of sodium salicylate in the sodium salicylate solution is 3 mg/ml.
The salicylic acid compound solution may be salicylic acid solution with salicylic acid content of 1-2 mg/ml. Specifically, the content of salicylic acid in the salicylic acid solution is 1 mg/ml, 1.5 mg/ml, 2 mg/ml and the like, and preferably, the content of salicylic acid in the salicylic acid solution is 1.5 mg/ml.
Alternatively, the salicylic acid compound solution may be a calcium acetylsalicylate urea solution containing calcium acetylsalicylate urea in an amount of 2 to 5 mg/ml, for example. Specifically, the content of calcium acetylsalicylate urea in the calcium acetylsalicylate urea solution is 2 mg/ml, 3.5 mg/ml, 4 mg/ml, 5 mg/ml and the like, and preferably, the content of calcium acetylsalicylate urea in the calcium acetylsalicylate urea solution is 3 mg/ml.
The stirring in steps S110 and S130 is performed by a magnetic stirrer, for example. The stirring can also be achieved by using other suitable stirrers than magnetic stirrers.
The content of silver ions in the intermediate solution prepared in step S110 may be, for example, 0.4 to 0.8 mg/ml, the content of tannic acid in the tannic acid solution may be, for example, 5 to 10 mg/ml, the content of sodium carbonate in the sodium carbonate solution may be, for example, 5 to 10 mg/ml, the content of polyvinylpyrrolidone in the polyvinylpyrrolidone solution may be, for example, 10 to 20 mg/ml, and the volume ratio of the intermediate solution, the tannic acid solution, the sodium carbonate solution, and the polyvinylpyrrolidone solution may be, for example, 88: 3: 2: 7. Specifically, the content of the silver ions in the intermediate solution may be, for example, 0.4 mg/ml, 0.55 mg/ml, 0.7 mg/ml, 0.8 mg/ml, etc., preferably 0.6 mg/ml. The content of tannic acid in the tannic acid solution may be, for example, 5 mg/ml, 7 mg/ml, 8.5 mg/ml, 10 mg/ml, etc., preferably 8 mg/ml. The sodium carbonate solution may contain sodium carbonate in an amount of, for example, 5 mg/ml, 5.5 mg/ml, 6 mg/ml, 8 mg/ml, 10 mg/ml, etc., preferably 7 mg/ml. The content of polyvinylpyrrolidone in the polyvinylpyrrolidone solution may be, for example, 10 mg/ml, 13 mg/ml, 16 mg/ml, 17.5 mg/ml, 20 mg/ml, etc., preferably 15 mg/ml.
Specifically, the average particle diameter of the nano silver particles in the antibacterial and antiviral nano silver colloidal solution is, for example, 42.30 nm.
Specifically, the zeta potential (Zetapontential) of the nano silver particles in the antibacterial and antiviral nano silver colloidal solution is, for example, -19.8 mV.
Several specific examples of the preparation method 100 of the antibacterial and antiviral nano-silver colloidal solution according to the first embodiment of the present invention to prepare the nano-silver colloidal solution will be given below to better illustrate the technical solution of the present invention, and the specific examples are as follows:
example 1: weighing appropriate amount of silver nitrate in the presence of a magnetic stirrer, preparing a solution with silver ion content of 0.4-0.8 mg/ml with 0.2% acetylsalicylic acid solution (acetylsalicylic acid content of 2 mg/ml), then 88 parts (the "parts" referred to herein and hereinafter refer to the volume of the solution) of the solution having the silver ion content of 0.4 to 0.8 mg/ml, in the presence of a magnetic stirrer, 3 parts of 0.5-1.0% tannic acid solution (the content of tannic acid is 5-10 mg/ml), 2 parts of 0.5-1.0% sodium carbonate solution (the content of sodium carbonate is 5-10 mg/ml) and 7 parts of 1.0-2.0% polyvinylpyrrolidone solution (the content of polyvinylpyrrolidone is 10-20 mg/ml) are slowly added in sequence to prepare the antibacterial and antiviral nano silver colloid solution which is stored in a brown bottle for later use. As shown in fig. 2, the Average particle diameter (shown as Z-Average (d.nm)) of the nano silver particles in the prepared antibacterial and antiviral nano silver colloidal solution was 42.30 nm, and as shown in fig. 3, the Zeta Potential (shown as Zeta Potential (mV)) of the nano silver particles was-19.8 mV.
Example 2: weighing appropriate amount of silver nitrate in the presence of a magnetic stirrer, preparing a solution with silver ion content of 0.4-0.8 mg/ml with 0.2-0.5% sodium salicylate solution (sodium salicylate content is 2-5 mg/ml), then 88 parts of the solution with the silver ion content of 0.4-0.8 mg/ml is taken, in the presence of a magnetic stirrer, 3 parts of 0.5-1.0% tannic acid solution (the content of tannic acid is 5-10 mg/ml), 2 parts of 0.5-1.0% sodium carbonate solution (the content of sodium carbonate is 5-10 mg/ml) and 7 parts of 1.0-2.0% polyvinylpyrrolidone solution (the content of polyvinylpyrrolidone is 10-20 mg/ml) are slowly added in sequence to prepare the antibacterial and antiviral nano silver colloid solution which is stored in a brown bottle for later use.
Example 3: weighing appropriate amount of silver nitrate in the presence of a magnetic stirrer, preparing a solution with silver ion content of 0.4-0.8 mg/ml with 0.1-0.2% salicylic acid solution (salicylic acid content of 1-2 mg/ml), then 88 parts of the solution with the silver ion content of 0.4-0.8 mg/ml is taken, in the presence of a magnetic stirrer, 3 parts of 0.5-1.0% tannic acid solution (the content of tannic acid is 5-10 mg/ml), 2 parts of 0.5-1.0% sodium carbonate solution (the content of sodium carbonate is 5-10 mg/ml) and 7 parts of 1.0-2.0% polyvinylpyrrolidone solution (the content of polyvinylpyrrolidone is 10-20 mg/ml) are slowly added in sequence to prepare the antibacterial and antiviral nano silver colloid solution which is stored in a brown bottle for later use.
Example 4: weighing appropriate amount of silver nitrate in the presence of a magnetic stirrer, preparing a solution with silver ion content of 0.4-0.8 mg/ml with 0.2-0.5% calcium acetylsalicylate urea solution (the content of calcium acetylsalicylate urea is 2-5 mg/ml), then 88 parts of the solution with the silver ion content of 0.4-0.8 mg/ml is taken, in the presence of a magnetic stirrer, 3 parts of 0.5-1.0% tannic acid solution (the content of tannic acid is 5-10 mg/ml), 2 parts of 0.5-1.0% sodium carbonate solution (the content of sodium carbonate is 5-10 mg/ml) and 7 parts of 1.0-2.0% polyvinylpyrrolidone solution (the content of polyvinylpyrrolidone is 10-20 mg/ml) are slowly added in sequence to prepare the antibacterial and antiviral nano silver colloid solution which is stored in a brown bottle for later use.
The preparation method 100 of the antibacterial and antiviral nano-silver colloidal solution provided by the embodiment of the invention can ensure that the prepared nano-silver colloidal solution has good broad-spectrum antibacterial and antiviral effects, solve the technical problem that the nano-silver colloidal solution in the prior art cannot well overcome the instability of nano-silver, and simultaneously enhance the broad-spectrum antibacterial and antiviral effects of the nano-silver in the nano-silver colloidal solution.
Example two
The second embodiment of the present invention provides an antibacterial and antiviral nano silver colloidal solution, which is prepared from raw materials including silver nitrate, salicylic acid compound solution, tannic acid solution, sodium carbonate solution and polyvinylpyrrolidone solution. The antibacterial and antiviral nano silver colloidal solution is prepared by using the preparation raw material and the preparation method 100 of the antibacterial and antiviral nano silver colloidal solution according to any one of the embodiments, and the preparation method 100 of the antibacterial and antiviral nano silver colloidal solution may refer to the description of the embodiments of the present invention, and is not repeated herein.
The antibacterial and antiviral nano-silver colloidal solution of the second embodiment of the present invention is prepared by the preparation method 100 of the antibacterial and antiviral nano-silver colloidal solution described in any one of the foregoing embodiments, so that the prepared nano-silver colloidal solution can be ensured to have good broad-spectrum antibacterial and antiviral effects, and simultaneously, the technical problem that the nano-silver colloidal solution in the prior art is not stable enough can be solved, and the broad-spectrum antibacterial and antiviral effects of the nano-silver in the nano-silver colloidal solution are enhanced.
Examples of the applications
It should be noted that the antibacterial and antiviral nano-silver colloidal solution according to any one of the embodiments of the present invention is a brand-new colloidal solution with multiple effects of broad-spectrum antibacterial, antifungal, antiviral, analgesic and anti-inflammatory, has no obvious toxic or side effect, has no drug resistance, has various application methods, and can be applied to the surface of an object, the surface of a fabric, the skin and a mucous membrane to inhibit the proliferation of various viruses, bacteria and fungi according to different dosage forms. Specific application methods of the antibacterial and antiviral nano silver colloid solution are shown in table 1, but include, but are not limited to, the application methods listed in table 1.
TABLE 1
| Type of colloidal solution | Application site | Object of action | Specific method of use |
| Example 1 Nano silver colloid solution | Skin, nasal cavity, throat and vagina | Bacteria, fungi and viruses | Spraying, smearing and rinsing |
| Example 2 Nano silverColloidal solution | Skin, nasal cavity and object surface | Bacteria, fungi and viruses | Spraying, smearing and rinsing |
| Example 3 Nano silver colloid solution | Skin, foot, nail and toenail | Bacteria and fungi | Spraying and smearing |
| Example 4 Nano silver colloid solution | Skin, nasal cavity, throat and vagina | Bacteria, fungi and viruses | Spraying, smearing and rinsing |
The antibacterial and antiviral nano-silver colloidal solution provided by the embodiment of the invention has a wide application prospect in the anti-infection field, and can be used for preparing various antibacterial and antiviral materials or antibacterial and antiviral drugs, such as medical dressings, external paints, resin products and the like, and specifically can be used for preparing band-aid, burn patches, burn and scald ointments, hand sanitizer, doors and windows, implantation instruments and the like.
Application effects
The following will describe the antibacterial and antiviral application effects of the antibacterial and antiviral nano-silver colloidal solution of the embodiment of the present invention in detail:
1. broad-spectrum antibacterial application: taking the nano-silver colloidal solution of the example 1, mixing the nano-silver colloidal solution with broth cultures of escherichia coli, staphylococcus aureus, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii and bacillus subtilis and a candida albicans broth culture in equal volume times, acting for different time at room temperature, and then applying a coating method to detect the inhibition effect of the colloidal solution on different bacteria. The experimental results show that the nano silver colloidal solution has extremely strong killing effect on the bacteria and the fungi, and the specific data of the experimental results are shown in table 2.
TABLE 2
| Strain (10)4cfu/ml) | 1min | 5min | 15min |
| Escherichia coli | 100 | 100 | 100 |
| |
100 | 100 | 100 |
| |
100 | 100 | 100 |
| |
100 | 100 | 100 |
| |
100 | 100 | 100 |
| |
100 | 100 | 100 |
| Candida albicans | 99.10 | 99.50 | 100 |
2. Broad spectrum antiviral applications: the nano-silver colloidal solution of example 1 was mixed with influenza virus (H1N1), influenza virus (H3N2), parainfluenza virus and newcastle disease virus solutions in equal volume, allowed to act at room temperature for 1 hour, and then diluted with physiological saline in equal volume on a 96-well hemagglutination plate, 0.1 ml of 0.5% chicken red blood cells (the content of chicken red blood cells is 5 mg/ml) was added dropwise to each well, mixed, allowed to act at room temperature for 1 hour, and the influence of the nano-silver colloidal solution on the blood coagulation activity of the four viral hemagglutinins was observed. The experimental result shows that the nano silver colloidal solution can obviously inhibit the blood coagulation activity of hemagglutinin of influenza virus (H1N1), influenza virus (H3N2), parainfluenza virus and Newcastle disease virus, and the nano silver colloidal solution has the effect of broad-spectrum resistance to respiratory virus infection, and the specific data of the experimental result is shown in Table 3.
TABLE 3
| Viral species | Hemagglutination potency of the experimental group | Hemagglutination titers of virus controls |
| Influenza virus (H1N1) | Has no hemagglutination activity | 1280 |
| Influenza virus (H3N2) | Has no hemagglutination activity | 1280 |
| Parainfluenza virus | Has no hemagglutination activity | 1280 |
| Newcastle disease virus | Has no hemagglutination activity | 1280 |
3. Broad-spectrum virucidal applications: the nano silver colloid solution of example 1 was mixed with influenza virus (H1N1), influenza virus (H3N2), parainfluenza virus and newcastle disease virus solution in equal volume for 1 hour at room temperature, then 0.1 ml of the mixed solution was inoculated into the allantoic cavity of 10-day-old chick embryos, 5 chick embryos per group were incubated at 38 ℃ for 72 hours, then placed in a 4 ℃ refrigerator overnight, the allantoic cavity solution was taken the next day, diluted with physiological saline in equal volume on a 96-well hemagglutination plate, 0.1 ml of 0.5% chicken red blood cells (the content of chicken red blood cells was 5 mg/ml) was added dropwise to each well, mixed, and allowed to act for 1 hour at room temperature to observe the inactivation of the nano silver colloid solution on these four viruses. The experimental result shows that the nano silver colloid solution can completely inactivate influenza virus (H1N1), influenza virus (H3N2), parainfluenza virus and Newcastle disease virus, the four viruses do not proliferate in allantoic cavities of 10-day-old chick embryos, and the specific data of the experimental result is shown in Table 4.
TABLE 4
| Viral species | Hemagglutination potency of the experimental group | Hemagglutination titers of virus controls |
| Influenza virus (H1N1) | Has no hemagglutination activity | 2560 |
| Influenza virus (H3N2) | Has no hemagglutination activity | 2560 |
| Parainfluenza virus | Has no hemagglutination activity | 1280 |
| Newcastle disease virus | Has no hemagglutination activity | 1280 |
In conclusion, in the embodiment of the invention, tannic acid and sodium carbonate are used as reducing agents in a salicylic acid compound solution, silver ions in silver nitrate are reduced to be nano silver, then a proper amount of polyvinylpyrrolidone is added to prepare a stable nano silver colloidal solution, the prepared nano silver colloidal solution has stable performance, is safe and effective, cannot generate drug resistance, and can directly act on proteins or enzyme proteins of various virosomes under the synergistic action of the salicylic acid compound and the nano silver, so that the capacity of virus infection of cells is reduced, and a broad-spectrum antiviral effect is exerted; the nano silver prepared by reducing tannic acid can inhibit the activity of surface protein and enzyme protein of bacteria, fungi and viruses, destroy the cell membrane structure of the bacteria, the fungi and the viruses, inhibit the template function of nucleic acid of the bacteria, the fungi and the viruses and play a broad-spectrum antibacterial and antiviral role.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments can be modified, or some technical features can be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (10)
1. The preparation method of the antibacterial and antiviral nano silver colloidal solution is characterized by comprising the following steps:
slowly adding silver nitrate into the salicylic acid compound solution and fully stirring to prepare an intermediate solution; and
and sequentially and slowly adding a tannic acid solution, a sodium carbonate solution and a polyvinylpyrrolidone solution into the intermediate solution, and fully stirring to prepare the antibacterial and antiviral nano-silver colloidal solution.
2. The method for preparing an antibacterial and antiviral nano-silver colloidal solution according to claim 1, further comprising the steps of: and storing the antibacterial and antiviral nano silver colloid solution in a brown bottle for later use.
3. The method for preparing an antibacterial and antiviral nano-silver colloidal solution according to claim 1, wherein the salicylic acid-based compound solution is any one selected from the group consisting of an acetylsalicylic acid solution, a sodium salicylate solution, a salicylic acid solution and a calcium acetylsalicylic acid urea solution.
4. The method for preparing nano silver colloidal solution for antibacterial and antiviral according to claim 3, wherein the content of acetylsalicylic acid in the acetylsalicylic acid solution is 2 mg/ml, the content of sodium salicylate in the sodium salicylate solution is 2 mg/ml to 5 mg/ml, the content of salicylic acid in the salicylic acid solution is 1 mg/ml to 2 mg/ml, and the content of calcium acetylsalicylic acid urea in the calcium acetylsalicylic acid urea solution is 2 mg/ml to 5 mg/ml.
5. The method for preparing an antibacterial and antiviral nano-silver colloidal solution according to claim 1, wherein the stirring is performed by a magnetic stirrer.
6. The method of preparing an antibacterial and antiviral nano silver colloidal solution as set forth in claim 1, wherein the content of silver ions in the intermediate solution is 0.4-0.8 mg/ml, the content of tannic acid in the tannic acid solution is 5-10 mg/ml, the content of sodium carbonate in the sodium carbonate solution is 5-10 mg/ml, the content of polyvinylpyrrolidone in the polyvinylpyrrolidone solution is 10-20 mg/ml, and the volume ratio of the intermediate solution, the tannic acid solution, the sodium carbonate solution and the polyvinylpyrrolidone solution is 88: 3: 2: 7.
7. The method of claim 6, wherein the nano silver particles in the nano silver colloidal solution have an average particle size of 42.30 nm.
8. The method of claim 6, wherein the zeta potential of the nano silver particles in the antibacterial and antiviral nano silver colloidal solution is-19.8 mv.
9. An antibacterial and antiviral nano silver colloidal solution, characterized in that it is prepared by the method of any one of claims 1 to 8.
10. The use of the nano silver colloidal solution for antibacterial and antiviral use according to claim 9 for preparing antibacterial and antiviral material or antibacterial and antiviral medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010326618.2A CN111408733A (en) | 2020-04-24 | 2020-04-24 | Antibacterial and antiviral nano silver colloidal solution and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010326618.2A CN111408733A (en) | 2020-04-24 | 2020-04-24 | Antibacterial and antiviral nano silver colloidal solution and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111408733A true CN111408733A (en) | 2020-07-14 |
Family
ID=71485779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010326618.2A Pending CN111408733A (en) | 2020-04-24 | 2020-04-24 | Antibacterial and antiviral nano silver colloidal solution and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111408733A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113813287A (en) * | 2021-08-27 | 2021-12-21 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Preparation method of compound medicinal liquid for treating verruca vulgaris |
| CN114470131A (en) * | 2020-10-23 | 2022-05-13 | 香港商富斐国际有限公司 | Preparation method of nano silver turmeric material applied to inhibiting novel coronavirus |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002245854A (en) * | 2001-02-20 | 2002-08-30 | Bando Chem Ind Ltd | Colloidal solution of metal, and manufacturing method of the same |
| JP2006299329A (en) * | 2005-04-19 | 2006-11-02 | Mitsuboshi Belting Ltd | Method for producing metal nanoparticle |
| US20070003603A1 (en) * | 2004-07-30 | 2007-01-04 | Karandikar Bhalchandra M | Antimicrobial silver compositions |
| CN101147977A (en) * | 2007-10-17 | 2008-03-26 | 楚雄师范学院 | Method for preparing high activity and long service negative charged colloidal nanometer silver |
| CN102579490A (en) * | 2012-02-22 | 2012-07-18 | 大连大学 | Nano-silver antiviral solution and preparation method thereof |
| JP2013185213A (en) * | 2012-03-08 | 2013-09-19 | Tokyo Institute Of Technology | Metal nanoparticle, method for producing the same, and conductive ink |
| CN103934469A (en) * | 2014-04-03 | 2014-07-23 | 湖北大学 | Method for preparing silver nanoclusters coated with glutathione |
| CN110883340A (en) * | 2018-09-10 | 2020-03-17 | 河南金渠银通金属材料有限公司 | Electronegative superfine silver powder and preparation method thereof |
-
2020
- 2020-04-24 CN CN202010326618.2A patent/CN111408733A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002245854A (en) * | 2001-02-20 | 2002-08-30 | Bando Chem Ind Ltd | Colloidal solution of metal, and manufacturing method of the same |
| US20070003603A1 (en) * | 2004-07-30 | 2007-01-04 | Karandikar Bhalchandra M | Antimicrobial silver compositions |
| JP2006299329A (en) * | 2005-04-19 | 2006-11-02 | Mitsuboshi Belting Ltd | Method for producing metal nanoparticle |
| CN101147977A (en) * | 2007-10-17 | 2008-03-26 | 楚雄师范学院 | Method for preparing high activity and long service negative charged colloidal nanometer silver |
| CN102579490A (en) * | 2012-02-22 | 2012-07-18 | 大连大学 | Nano-silver antiviral solution and preparation method thereof |
| JP2013185213A (en) * | 2012-03-08 | 2013-09-19 | Tokyo Institute Of Technology | Metal nanoparticle, method for producing the same, and conductive ink |
| CN103934469A (en) * | 2014-04-03 | 2014-07-23 | 湖北大学 | Method for preparing silver nanoclusters coated with glutathione |
| CN110883340A (en) * | 2018-09-10 | 2020-03-17 | 河南金渠银通金属材料有限公司 | Electronegative superfine silver powder and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陈艳等: "银溶胶中水杨酸吸附行为的实验和密度泛函理论研究", 《信阳师范学院学报：自然科学版》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470131A (en) * | 2020-10-23 | 2022-05-13 | 香港商富斐国际有限公司 | Preparation method of nano silver turmeric material applied to inhibiting novel coronavirus |
| CN113813287A (en) * | 2021-08-27 | 2021-12-21 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Preparation method of compound medicinal liquid for treating verruca vulgaris |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11591217B2 (en) | Antipathogenic devices and methods thereof | |
| US20070134136A1 (en) | Disinfecting composition | |
| US20070218555A1 (en) | Anti-Microbial Activity Of Biologically Stabilized Silver Nano Particles | |
| CA2761710C (en) | Methods of treating or preventing influenza associated illness with oxidative reductive potential water solutions | |
| US8673331B2 (en) | Composition with sterilizing activity against bacteria, fungus and viruses, application thereof and method for preparation thereof | |
| CN101437504A (en) | Metal-containing virucidal compositions and uses | |
| CN111408733A (en) | Antibacterial and antiviral nano silver colloidal solution and preparation method and application thereof | |
| US20160000088A1 (en) | Process for producing silver-ion antibacterial liquid, silver-ion antibacterial liquid produced by said process, and silver-ion-containing product containing said antibacterial liquid | |
| CN104430311A (en) | Active bactericidal medicine as well as preparation method and special equipment thereof | |
| KR20170033925A (en) | Spray compositions having antiviral efficacy and antibacterial agent | |
| WO2010134942A1 (en) | Electrostatically charged multi-acting nasal application, product and method | |
| CN104524559A (en) | Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof | |
| EP0148709A1 (en) | Improved germicide composition | |
| CN109497107A (en) | A kind of composition can be used as air sanitizer | |
| CN104026150A (en) | Composite liquid for preventing and killing avian influenza viruses and preparation method and application thereof | |
| KR20230145023A (en) | Compositions and methods for disinfecting, treating and preventing microbial infections | |
| EP4021462A1 (en) | Transmission prevention of viruses with application of antiseptic composition | |
| CN111214409A (en) | No-clean disinfectant and preparation method thereof | |
| CN111575119A (en) | Photocatalytic disinfection and sterilization self-cleaning agent | |
| CN109512692B (en) | Antibacterial additive solution for wet tissue and preparation method thereof | |
| US20220160673A1 (en) | Method preparing silver-nanocurcumin material for inhibiting new coronavirus | |
| AU2021203846B2 (en) | Virucidal formulations containing povidone-iodine | |
| CN107095901A (en) | A kind of antibacterial agent | |
| Mathoor et al. | Antimicrobial Activity of Aparajitha Vaporizer and Spray | |
| Kenjaevich et al. | Preclinical study of drug forms based on chitosan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200714 |